Evidence map›Paper›PMID 22168993›Full record

ArticleArthritis research & therapy2011

Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease.

Lodewijk de Groot, Helmy Hinkema, Johanna Westra, Andries J Smit, Cees G M Kallenberg, Marc Bijl, Marcel D Posthumus

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07329556 (Evaluation of Advanced Glycation End Products Accumulation in Rheumatic Diseases Using Non-Invasive Skin Autofluorescence Measurements), which is not on this map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07329556 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of Advanced Glycation End Products Accumulation in Rheumatic Diseases Using Non-Invasive Skin Autofluorescence Measurements

TypeobservationalSponsorBursa City HospitalRan2026 to 2027Enrolled300ConditionsRheumatoid Arthritis (RA, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis (ReA)
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. A systematic review and meta-analysis of circulating adhesion molecules in rheumatoid arthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Glycation in the cardiomyocyte.Vitamins and hormones · 2024
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lodewijk de GrootDepartment of Rheumatology and Clinical Immunology, University Medical Centre, University of Groningen, Groningen, The Netherlands. lodewijk.de.groot@reuma.umcg.nl
Helmy Hinkema
Johanna Westra
Andries J Smit
Cees G M Kallenberg
Marc Bijl
Marcel D Posthumus
University Medical Center Groningen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAdvanced glycation end products (AGEs) are produced and can accumulate during chronic inflammation, as might be present in patients with rheumatoid arthritis (RA). AGEs are involved in the development of cardiovascular disease. The aim of this study is to evaluate whether AGEs are increased in patients with long-standing RA and whether AGE accumulation is related to disease activity, disease severity and measures of (premature) atherosclerosis, such as endothelial activation, endothelial dysfunction and intima media thickness (IMT).

methodsIn a cross-sectional study, 49 consecutive RA patients with longstanding disease (median disease duration of 12.3 years (range 9.3 to 15.1)), receiving standard of care, were included and compared with 49 age- and sex-matched healthy controls (HC). AGEs were determined by skin autofluorescence. Disease activity was evaluated by the Disease Activity Score of 28 joints (DAS-28) score and joint damage by modified Sharp-v.d. Heijde score. Endothelial activation (soluble vascular cellular adhesion molecule-1) sVCAM-1, von Willebrand factor (vWF), thrombomodulin), endothelial dysfunction (determined by small artery elasticity (SAE)) and IMT were measured and related to AGE accumulation.

resultsAGEs were increased in RA patients (median 2.4 arbitrary units (a.u.), range 1.6 to 4.2) compared to HC (2.2, 1.3 to 3.8). RA patients had a DAS-28 score of 2.9 (0.8 to 6.9) and a modified Sharp-v.d. Heijde score of 19 (0 to 103). sVCAM-1 and vWF levels were higher in RA patients. SAE was significantly decreased in RA (3.9 ml/mmHg (1.4 to 12.2) vs. 6.1 in HC (1.7 to 12.9). IMT did not differ between the two groups. Combining both groups' AGEs correlated with vWF, sVCAM-1 and IMT, and was inversely related to SAE. In RA, AGEs had an inverse relation with SAE, but did not relate to disease activity or radiological damage. In multivariate analysis for both groups, smoking, glucose levels, vWF, SAE and male gender were significantly related to the formation of AGEs.

conclusionsAGEs were increased in RA patients with long-standing disease and without signs of premature atherosclerosis. AGEs were related to endothelial activation and endothelial dysfunction. This supports the hypothesis that in RA AGEs may be an early marker of cardiovascular disease.

Indexed as

AdultAgedArthritis, RheumatoidAtherosclerosisBiomarkersCarotid Intima-Media ThicknessCase-Control StudiesC-Reactive ProteinCross-Sectional StudiesEndothelium, VascularFemaleGlycation End Products, AdvancedHumansJointsLinear ModelsMaleBiomarkersC-Reactive ProteinGlycation End Products, AdvancedThrombomodulinVascular Cell Adhesion Molecule-1von Willebrand Factor

Identifiers

PMID22168993
PMCPMC3334658
OpenAlexW2153661389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.